Jump Financial LLC raised its stake in shares of Enovis Co. (NYSE:ENOV – Free Report) by 187.0% during the third quarter, Holdings Channel.com reports. The institutional investor owned 11,469 shares of the company’s stock after buying an additional 7,473 shares during the period. Jump Financial LLC’s holdings in Enovis were worth $605,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also made changes to their positions in the stock. Neuberger Berman Group LLC purchased a new stake in Enovis in the 1st quarter valued at about $905,000. JPMorgan Chase & Co. acquired a new position in Enovis during the second quarter worth approximately $5,573,000. Bank of Montreal Can acquired a new position in Enovis during the second quarter worth approximately $532,000. UBS Group AG purchased a new position in Enovis during the second quarter worth approximately $1,211,000. Finally, FMR LLC purchased a new position in Enovis during the second quarter worth approximately $3,016,000. 98.45% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of equities analysts have weighed in on the stock. UBS Group assumed coverage on shares of Enovis in a research note on Monday, January 22nd. They set a “buy” rating and a $75.00 price target on the stock. William Blair started coverage on shares of Enovis in a research report on Wednesday, January 3rd. They issued an “outperform” rating for the company. Needham & Company LLC increased their price objective on shares of Enovis from $70.00 to $73.00 and gave the stock a “buy” rating in a research report on Monday, January 8th. Canaccord Genuity Group increased their price objective on shares of Enovis from $65.00 to $71.00 and gave the stock a “buy” rating in a research report on Wednesday, December 20th. Finally, Roth Mkm started coverage on shares of Enovis in a research report on Friday, October 20th. They issued a “buy” rating and a $75.00 price objective for the company. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $71.83.
Enovis Price Performance
ENOV opened at $60.53 on Friday. The company has a fifty day simple moving average of $56.30 and a 200 day simple moving average of $53.94. The firm has a market cap of $3.30 billion, a price-to-earnings ratio of -44.18 and a beta of 2.00. Enovis Co. has a twelve month low of $43.04 and a twelve month high of $66.14. The company has a current ratio of 2.40, a quick ratio of 1.08 and a debt-to-equity ratio of 0.11.
Enovis (NYSE:ENOV – Get Free Report) last announced its quarterly earnings data on Tuesday, November 7th. The company reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.54 by $0.02. The company had revenue of $417.50 million during the quarter, compared to analyst estimates of $414.89 million. Enovis had a negative net margin of 4.51% and a positive return on equity of 3.70%. The firm’s revenue for the quarter was up 8.8% compared to the same quarter last year. During the same period last year, the business earned $0.59 EPS. Equities research analysts expect that Enovis Co. will post 2.37 EPS for the current fiscal year.
Enovis Company Profile
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufacture and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.
- Five stocks we like better than Enovis
- 3 Healthcare Dividend Stocks to Buy
- The 5 best small cap AI companies to buy now
- How to Invest in Artificial Intelligence
- Cirrus Logic: A chip stock you’re going to hear a lot more about
- Investing in the High PE Growth Stocks
- Archer Aviation’s sky-high progress and short interest
Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.